Invention Application
- Patent Title: EXTRACELLULAR VESICLES DERIVED FROM ACTIVATED CAR-T CELLS
-
Application No.: US17604169Application Date: 2020-04-16
-
Publication No.: US20220204928A1Publication Date: 2022-06-30
- Inventor: Anat AHARON , Anat GLOBERSON LEVIN , Irit AVIVI , Galit HORN , Tova WAKS , Zelig ESHHAR
- Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. , ICHILOV TECH LTD.
- Applicant Address: IL Reehovot; IL Tel Aviv
- Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.,ICHILOV TECH LTD.
- Current Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.,ICHILOV TECH LTD.
- Current Assignee Address: IL Reehovot; IL Tel Aviv
- Priority: IL266153 20190418
- International Application: PCT/IL2020/050444 WO 20200416
- Main IPC: C12N5/0783
- IPC: C12N5/0783 ; C07K16/32 ; C07K14/705 ; C07K14/725 ; A61K45/06 ; A61K39/395 ; A61K38/17 ; A61P35/00 ; A61K35/17 ; C07K16/28
Abstract:
The present invention provides extracellular vesicles (EVs) derived from T-cells expressing chimeric antigen receptors (CAR) specifically activated with an antigen to which the CAR bind specifically, pharmaceutical compositions comprising these vesicles as well as their use in treating cancer. In particular the present invention exemplifies EVs derived from activated T-cells expressing CAR that bind specifically to HER2 cancer antigen, pharmaceutical composition comprising these EVs and their use in treating a cancer overexpressing HER2, such as ovarian cancer and breast cancer.
Information query
